Effect of Glucocorticoid Use in Patients With Biopsy‐Proven Acute Interstitial Nephritis: Insights From a Colombian Cohort

<b>Introduction:</b> Acute interstitial nephritis (AIN) is a major cause of acute kidney injury, commonly triggered by medications or infections. Although glucocorticoid (GC) therapy is recommended for patients who do not improve after removing the suspected cause, the evidence supporting its use remains limited. <b>Materials and Methods:</b> This retrospective cohort study was conducted at the Pathology Unit of the University of Antioquia-San Vicente Fundación Hospital in Medellín, Colombia, reviewing patients aged 14 and older with biopsy-proven AIN over an 11-year period. Two groups were formed based on whether or not they received GC treatment. Key outcomes included changes in delta creatinine (serum creatinine change from peak to 6-month follow-up) and the need for permanent kidney replacement therapy. Linear regression analyses assessed factors influencing delta creatinine at 6 months, adjusting for age, clinical severity, time to GC initiation, and histological findings. <b>Results:</b> Of 139 eligible patients, 101 received GC therapy. The GC-treated group showed a significantly greater reduction in delta creatinine compared to the nontreated group (-2.3 mg/dL; 95% CI, -3.6 to -1.1, <i>p</i> < 0.001). Multivariate analysis identified GC therapy as an independent predictor of improved kidney function (delta creatinine reduction: -1.47 mg/dL; 95% CI, -2.68 to -0.27, <i>p</i>=0.017), particularly when initiated within 7 days of diagnosis. The GC-treated group also had a lower incidence of permanent dialysis dependence (54% at admission vs. 11% at 6 months). Adverse events occurred in 20.1% of the cohort, with a higher frequency in the GC group (<i>p</i>=0.076). <b>Conclusion:</b> GC therapy may improve kidney outcomes in patients with biopsy-proven AIN, especially when initiated early. These results support the need for prospective studies to further evaluate its efficacy in AIN management.

Authors

Institutions

Publication Details

Journal
International Journal of Nephrology
Published
2025-01-01
DOI
https://doi.org/10.1155/ijne/9980649
Citations
1
Primary Topic
Nephrotoxicity and Medicinal Plants
Type
article
Field-Weighted Citation Impact
1.36

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Effect of Glucocorticoid Use in Patients With Biopsy‐Proven Acute Interstitial Nephritis: Insights From a Colombian Cohort

Luis Fernando Arias-Restrepo, Mauricio Restrepo‐Escobar, Laura Camila Lopera-Restrepo, Joaquín Roberto Rodelo-Ceballos et al.
1 citations
International Journal of Nephrology
Nephrotoxicity and Medicinal Plants
1.36
article

Effect of Glucocorticoid Use in Patients With Biopsy‐Proven Acute Interstitial Nephritis: Insights From a Colombian Cohort

Luis Fernando Arias-Restrepo, Mauricio Restrepo‐Escobar, Laura Camila Lopera-Restrepo, Joaquín Roberto Rodelo-Ceballos, Camilo Andrés García-Prada, Angie Pinto-Diaz
article en
1 citations

Abstract

<b>Introduction:</b> Acute interstitial nephritis (AIN) is a major cause of acute kidney injury, commonly triggered by medications or infections. Although glucocorticoid (GC) therapy is recommended for patients who do not improve after removing the suspected cause, the evidence supporting its use remains limited. <b>Materials and Methods:</b> This retrospective cohort study was conducted at the Pathology Unit of the University of Antioquia-San Vicente Fundación Hospital in Medellín, Colombia, reviewing patients aged 14 and older with biopsy-proven AIN over an 11-year period. Two groups were formed based on whether or not they received GC treatment. Key outcomes included changes in delta creatinine (serum creatinine change from peak to 6-month follow-up) and the need for permanent kidney replacement therapy. Linear regression analyses assessed factors influencing delta creatinine at 6 months, adjusting for age, clinical severity, time to GC initiation, and histological findings. <b>Results:</b> Of 139 eligible patients, 101 received GC therapy. The GC-treated group showed a significantly greater reduction in delta creatinine compared to the nontreated group (-2.3 mg/dL; 95% CI, -3.6 to -1.1, <i>p</i> < 0.001). Multivariate analysis identified GC therapy as an independent predictor of improved kidney function (delta creatinine reduction: -1.47 mg/dL; 95% CI, -2.68 to -0.27, <i>p</i>=0.017), particularly when initiated within 7 days of diagnosis. The GC-treated group also had a lower incidence of permanent dialysis dependence (54% at admission vs. 11% at 6 months). Adverse events occurred in 20.1% of the cohort, with a higher frequency in the GC group (<i>p</i>=0.076). <b>Conclusion:</b> GC therapy may improve kidney outcomes in patients with biopsy-proven AIN, especially when initiated early. These results support the need for prospective studies to further evaluate its efficacy in AIN management.

International Journal of NephrologyVol. 2025(1)
Hospital Universitario de San Vicente Fundación (CO), Universidad de Antioquia (CO)
Universidad de Antioquia
Good health and well-being
Openalex Percentile: Top 21%
Nephrotoxicity and Medicinal Plants
1.36
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.